Information Hub

Clinical News

2017-12-29

Pembrolizumab and trastuzumab combined show clinical activity in HER2-positive breast cancer

Based on the results of a phase Ib/II PANACEA trial, pembrolizumab and trastuzumab exhibited response in HER2-positve breast cancer.

Source:

Onclive

2017-12-29

Pembrolizumab exhibits antitumor activity in advanced cervical cancer

Based on the results of a cervical cancer cohort in KEYNOTE-028 trial, pembrolizumab showed durable antitumor activity in advanced cervical cancer.

Source:

CancerNetwork ; Publication

2017-12-29

Loss of heterozygosity at specific sites in BRCA1/2 germline mutation affects the response of treatment

It was found that breast or ovarian tumors with LOH at BRCA1/2 is associated with sensitivity to drug response. Locus-specific LOH can be a kind of biomarker to evaluate the effectiveness of DNA damaging drugs in patients with germline BRCA1/2 mutation.

Source:

Nature

2017-12-29

FDA authorized MSKCC’s tumor profiling test

The U.S. Food and Drug Administration (FDA) approved Memorial Sloan Kettering Cancer Center’s (MSKCC) tumor profiling test as an in vitro diagnostics (IVD).

Source:

FDA News

2017-12-29

Larotrectinib showed excellent efficacy in pediatric cancer with TRK fusion

An updated phase I clinical trial data revealed the efficiency of larotrectinib in pediatric cancer with TRK fusion.

Source:

Loxo Oncology

2017-12-01

Pembrolizumab shows clinical activity in advanced sarcoma

Based on the results of a single-arm, phase 2 SARC028 study, pembrolizumab exhibited response in two subtypes of advanced sarcoma: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Source:

Publication : Lancet Oncol. 2017 Oct 4. pii: S1470-2045(17)30624-1. doi: 10.1016/S1470-2045(17)30624-1.

2017-12-01

Driver mutations can be detected in advanced NSCLC via liquid biopsy

At the International Association for the Study of Lung Cancer (IASLC) Annual Conference in Japan this year, a research shows that liquid biopsy is able to detect unknown driver mutations in advanced non-small cell lung cancer (NSCLC) using next-generation

Source:

Cancer Therapy Advisor

2017-12-01

Entrectinib showed promising data for patients with ROS1 fusion-positive advanced non–small cell lung cancer

The results of the clinical trial on treating ROS1 fusion-positive patients of advanced non-small cell lung cancer with entrectinib were presented at the 18th World Conference on Lung Cancer (WCLC). Entrectinib showed clinical benefits and tolerable adver

Source:

https://ignyta.com/investors/press-release-article/1044289/

2017-12-01

A preliminary data of Poziotinib showed significant antitumor activity in patients with EGFR exon 20 insertion non–small cell lung cancer

A preliminary analysis of a phase II clinical trial data of poziotinib that treats non-small cell lung cancer patients with EGFR exon 20 insertion was presented at the 18th World Conference on Lung Cancer (WCLC). Poziotinib was confirmed to have significa

Source:

http://www.ascopost.com/News/58167

2017-12-01

Following germline cancer genetic testing guideline would not detect all heritable cancer gene information

Following cancer genetic testing guideline to screen target patients and gene list may miss some heritable gene mutations. MSKCC cancer center suggests using broad cancer-related gene panels, which provides more comprehensive information to evaluate the g

Source:

Genomeweb